HIV / AIDS

The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.

The largest head-to-head randomized clinical trial confirms results and also shows the 2-therapy regimen led to less weight gain.

Jared Baeten, MD, PhD emphasizes the importance of the innovative PURPOSE 1 study in the fight against HIV, coinciding with National HIV Testing Day, today serves as a reminder of the ongoing efforts to expand testing access and develop new tools to combat HIV globally.

Experts on HIV offer insights into switching therapies for patients with a history of resistance, highlighting ways to simplify and optimize treatment.

Zero HIV infections from the Phase 3 PURPOSE 1 Trial underscore the importance of innovative HIV prevention strategies across diverse populations.

Focusing on the importance of rapid treatment initiation in HIV, Shauna Applin, ARNP, reviews available therapies and provides clinical insights on treatment considerations.

Shauna Applin, ARNP, provides an overview of the therapeutic algorithm for patients with HIV, highlighting treatment guidelines and currently available therapies.

A panel of experts on HIV discuss decision-making practices for patients who have suboptimal response to their current treatment regimen.

Focusing on the management of patients with HIV, the panel provides clinical insights on treatment selection, focusing on long-acting agents.

The panel discusses strategies to predict patients who will have poor adherence to their HIV medications and how to select the best treatment options for them.

Experts on HIV provide clinical insights on testing for drug resistance prior to treatment and approaching the topic of resistance with patients.

Paul E. Sax, MD, and Sorana Segal-Maurer, MD, discuss treatment resistance in HIV and how it has changed over the years.

The panel discusses the importance of starting HIV treatment early after diagnosis and offers advice to clinical providers.

Experts on the treatment of HIV discuss how they talk with their patients about adverse effects associated with HIV regimens.

The panel offers expert perspectives on key factors that inform treatment decisions for patients with HIV.

This report underscores the increase of STIs alongside the ongoing global epidemics of HIV and viral hepatitis in the Americas and African regions.

Efforts among organizations aim to develop innovative vaccine candidates and advancements in the global fight against HIV.

Focusing on the evolving treatment paradigms for HIV, the panel reviews guideline recommendations for initial therapy and discusses education practices for newly diagnosed patients.

A panel of experts on HIV open the discussion with a conversation about the role of the primary care provider and advanced practice provider in treating patients with HIV.

A Centers for Disease Control and Prevention (CDC) investigator offers insights into their investigation of customers receiving vampire facials (a spa cosmetic procedure) and contracting the virus afterwards.

FDA-approves mpox vaccine, FDA grants EUA for at-home multiplex papid test, FDA grants PDUFA for GSK 5-in-1 meningococcal vaccine, and more this month from the FDA.

New data reinforced the safety and tolerability profile of this antiretroviral therapy for this patient population who are virologically suppressed.

Study evaluates the outcomes of orthotopic liver transplantation of HIV-HBV coinfected patients.

New data shows young children are less likely to get diagnosed and get into the continuum of care including getting prescribed antiretroviral therapy (ART).

The CDC's take on the importance of HIV awareness and testing among our youth.

The federal agency has given the nod for dolutegravir/lamivudine (Dovato) for teens living with the virus and offers a novel option for patients.

Here is a case study involving a patient with the virus and the clinical approach in thinking about appropriate treatment while keeping stewardship in mind.

The role of the US President’s Emergency Plan for AIDS Relief in combating tuberculosis (TB).

This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.

Study proves the role of harnessing CrAgSQ for management over the infection.